Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review

Virginia Calvo¹, Belén Sierra-Rodero²,³, Alberto Cruz-Bermúdez², Mariano Provencio¹

¹Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; ²Instituto de Investigación Sanitaria Puerta de Hierro-IDIPHISA, Majadahonda, Madrid, Spain; ³PhD Programme in Molecular Biosciences, Doctoral School, Universidad Autónoma de Madrid, Madrid, Spain

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Mariano Provencio. Department of Medical Oncology, Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Majadahonda, Madrid, Spain. Email: mprovenciop@gmail.com.

Abstract: Non-small cell lung cancer (NSCLC) is one of the main leading causes of death by cancer worldwide. Approximately one third of cases are diagnosed at stage III, whose therapeutic strategy based on multimodal treatment has reached a plateau of effectiveness. Treatment with anti-PD-1/PD-L1 [anti-PD-(L)1] antibodies have been established in advanced stages due to their improved clinical benefit and acceptable profile of related adverse events. Lately, numerous clinical trials have been designed with diverse approaches to introduce immunotherapy into stages IIIA. The objective of this review is to discuss the different strategies that are being taken in the ongoing clinical trials, taking into account the peculiarities of stage IIIA and the tumor microenvironment. PubMed, major international conferences and clinicaltrials.gov databases were searched from Jan 1, 1990, to May 11, 2020 using the terms NSCLC, stage III, resectable, unresectable, immunotherapy, checkpoint inhibition, neoadjuvant and adjuvant. In this review we describe, in the context of stage IIIA disease, the impact of anti-PD-(L)1 and conventional therapies on the tumor microenvironment. Moreover, we describe the role of immunotherapy, through the heterogeneous landscape of stage IIIA NSCLC, summarizing ongoing clinical trials in incidental, potentially resectable, and unresectable tumors. We finally discuss the potential of PD-L1, TMB, and TCR repertoire analysis as predictive biomarkers in stage IIIA NSCLC. Initial results seem to favor neoadjuvant over adjuvant treatment, with chemoimmunotherapy combination standing out. Ongoing trials will answer whether immunotherapy can transform stage IIIA from lethal to a curable disease. Additionally, higher pathological response rates observed, open the possibility to establishing it as survival surrogate, speeding up the potential immunotherapy implementation in stage IIIA NSCLC.

Keywords: Lung cancer; immune checkpoint inhibitors; immunotherapy; locally advanced; stage IIIA

Received: 15 April 2020. Accepted: 08 July 2020.
doi: 10.21037/ccts-20-82
View this article at: http://dx.doi.org/10.21037/ccts-20-82

Introduction

Lung cancer is the leading cause of cancer-related death in both genders worldwide (1). Approximately 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Of patients with NSCLC, at diagnosis, 20% present with stage I or II, whereas 30% present with stage III, locally advanced disease, and 50% of patients with stage IV disease. Five-year survival rate of patients with stage I NSCLC is approximately 70–90%, whereas stage II to III NSCLC patients, have a 5-year survival rate of approximately 25% to 60% (2).
Stage III NSCLC is a heterogeneous disease. In the 8th edition of the TNM classification, stage III NSCLC includes M0 patients, who present N2 or N3 disease, a tumor with T4 features or one categorized as T3N1 (3). Stage IIIA includes T4N0 and T3/4N1 tumors as well as T1/T2 N2 tumors.

Thus, the stage IIIA management is complex including patients with resected, potentially resectable and unresectable tumors and therefore their treatment should be deliberated by a multidisciplinary team (4). Outcomes remain poor, even in the case of potentially resectable tumors, with a median progression-free survival (PFS) of 13 months and a 3-year overall survival (OS) rate of 30% for this subset of patients, without major changes in the last 25 years (5).

In the last few years, cancer immunology knowledge has experienced a remarkable advance, leading to use immunotherapy against cancer (6). In March 2015, the FDA approved an anti-PD-1 antibody (Nivolumab) as a second-line treatment in metastatic NSCLC since it produces a significant increase in overall survival (OS) of stage IV patients. Since then, this type of treatment has been positioned as the first choice for different histologies, becoming the main therapy in advanced stages of NSCLC (7).

At the present time, immunotherapy has new challenges ahead, as the stage IIIA scenario.

There are currently dozens of phase two and three clinical trials, both monotherapy and immunotherapy combinations, addressing this complex task of bringing immunotherapy closer to stage IIIA clinical practice, the results of which will be known during the next few years.

Therefore, in this changing scenario of great development and clinical relevance, it is necessary to discuss the current knowledge and the possible role of immunotherapy in stage IIIA.

For this purpose, in this narrative review we describe the tumor microenvironment as therapy target, as well as, the different strategies that are being taken in the ongoing clinical trials, taking into account the specific vicissitudes of stage IIIA NSCLC.

We present the following article in accordance with the narrative review reporting checklist (available at http://dx.doi.org/10.21037/ccts-20-82).

Methods
We searched PubMed from Jan 1, 1990, to May 11, 2020, employing the following search words alone or in combination: NSCLC, stage III, resectable, unresectable, immunotherapy, checkpoint inhibition, neoadjuvant and adjuvant.

Additionally, relevant ongoing clinical trials included in this review were found in clinicaltrials.gov database, using “stage III NSCLC” as search term, and limiting the search to completed, not yet recruiting, recruiting, enrolling by invitation, and active but not recruiting enrolling status. Further information was collected by consulting major international conferences (IASLC, ESMO and ASCO meeting databases), applying the name of the trial and NTC number.

Discussion
Treatments and tumor immune microenvironment
An emerging hallmark of cancer is the cancer cell’s ability to avoid destruction by the immune system, known as Immunoevasion. The three general categories of immunoreactive mechanisms include: an insufficient number of T-cells generated within the lymphoid compartment; an insufficient number of T-cells extravasating into the tumor; and inhibition of T-cells in the tumor microenvironment.

The tumor microenvironment, in turn, offers three main immunoreactive tools: surface membrane proteins that function as immune checkpoints, including PD-1, CTLA-4, lymphocyte-activation gene 3 (LAG-3) protein, T-cell immunoglobulin and mucin domain–containing protein 3 (TIM-3), B- and T-lymphocyte attenuator (BTLA), and the adenosine A2a receptor (A2aR); the relationship between selected soluble factors and metabolic alterations, such as IL-10, transforming growth factor beta, adenosine, indoleamine 2,3-dioxygenase (IDO), and arginase; and inhibitory cells, including cancer-associated fibroblasts (CAFAs), regulatory T-cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) (8-11).

Anti-PD-1/PD-L1 and tumor immune microenvironment
PD-L1 overexpression has been observed in 30–50% of all NSCLC tumors across all stages and histologies. However, PD-L1 positivity has been associated with male gender, smoking status, higher T and N status, advanced tumor grade and stage, and wild-type EGFR (12,13).

Anti-PD-1/PD-L1 antibodies activity is based on the blockade of PD-1 protein in lymphocytes or PD-L1 in tumor cells, preventing lymphocytes
inactivation and promoting tumor elimination. A great part of the knowledge of its mechanism is due to neoadjuvant immunotheraphy studies. In the situation with the intact tumor, on one side, anti-PD-(L)1 rejuvenates the tumor-specific cytotoxic T-cells from the tumor microenvironment, causing them to activate, proliferate and mobilize to eliminate distant micrometastasis. Additionally, anti-PD-(L)1 increase tumor antigen presentation by dendritic cells in the tumor draining lymph nodes activating new tumor-specific T-cells that then migrate to tumor sites (14). Both processes trigger a powerful systemic anti-tumor immune response and the generation of memory T-cells that may provide long-term protection (15-18).

Conversely, the neoantigen repertoire is reduced when the primary tumor is resected, limiting this anti-tumor immune response in the adjuvant setting and representing a strong argument for neoadjuvant approach. Moreover, several immunological pathways are disrupted by surgical stress (19). While essential for wound healing, surgical stress leads to expansion of regulatory T-cells, MDSC, and M2 macrophages, resulting in an overall state of immunosuppression with PD-1/CTLA-4 increase and T-cell exhaustion. Immune checkpoint inhibitors (ICI) in neoadjuvant setting might be advantageous activating tumor infiltrating T-cells prior to surgery, and avoiding PD-1 expression on immune cells in the postoperative period.

However, the impact of anti-PD-(L)1 antibodies is true as long as there are no other elements governing the activity of cytotoxic lymphocytes as mentioned before (20). Perhaps for this reason, the presence of PD-L1 in tumor cells has not been a perfect marker of response to treatment, so that today, it is not clear which patients will benefit more from the treatment (21).

**Chemo-radiotherapy and tumor immune microenvironment**

Although cancer chemo-radiotherapy has generally been associated to immunosuppression, it is now established that certain drugs, such as paclitaxel, cisplatin, carboplatin and gemcitabine, as well as, specific tumor radiation, can regulate and modulate antitumor immunity. In fact, many studies are being based on chemo-radioimmunotherapy combinations (22-24). Chemo-radiotherapy has the ability to obtain an anti-tumor immune response by inducing immunogenic tumor cell death and subsequent release of tumor-associated antigens, which ultimately activates antigen-presenting cells (25).

NSCLC tumors after neoadjuvant chemotherapy presented higher levels of PD-L1+ tumor cells and tumor infiltrating lymphocytes than those who underwent upfront surgery without neoadjuvant treatment. Higher levels of helper T-cells and TAMs were associated to increased survival in NSCLC patients treated with neoadjuvant chemotherapy (26).

Paclitaxel increase the levels of CD8+ T-cells secreting IFN-γ as well as CD4+ T-cells secreting IL-2, associated to antitumor immune responses (27). Additionally, paclitaxel hampers regulatory T-cells viability and immunosuppressive cytokine production maintaining CD4+ effector T-cell function (28).

Platinum chemotherapy alters the levels of myeloid cells increasing dendritic cells and reducing MDSCs, thus favoring immune effector responses. Decreased iNOS, IDO and IL-4R expression after platinum-based therapy has been observed in a serial analysis of blood samples from NSCLC patients (29).

Ablative radiation therapy increases immunogenic tumor cell death and T-cell priming in draining lymphoid tissues promoting tumor elimination. As a consequence, distant metastases may be eliminated in a CD8+ T-cell dependent fashion, a process denominated abscopal effect, which is not well understood yet (22).

**Incidental stage IIIA**

Incidental stage IIIA includes patients with previously unknown N2 disease revealed during surgery. The reduced local control and OS after surgery in these patients makes them suitable for adjuvant chemotherapy. Adjuvant platinum-based chemotherapy has been associated to a 5% OS increase at 5 years (30,31).

The impact of radiotherapy after surgery is still under debate since it diminish local relapse risk without improving OS (32,33). Currently, for stage II–IIIA resectable NSCLC the standard treatment is still radical surgery (lobectomy/ pneumonectomy) followed by 4 cycles of adjuvant chemotherapy (CT) with a platinum-based doublet (34). Despite the available treatments, the survival of completely resected NSCLC remains poor and this is the reason why it is necessary to evaluate new strategies of management.

The use of ICI in the adjuvant setting is evaluated in different solid tumors such as lung, bladder, esophageal, colorectal, ovarian cancer and some others (35). However, melanoma is the first tumor in which immunotherapy has been demonstrated efficacy after surgery. The first ICI approved in this context was ipilimumab (anti-CTLA4)
(36), followed by nivolumab (37) and pembrolizumab (anti-PD-1) (38).

Currently, four randomized phase III clinical trials which are evaluating the role of immunotherapy in patients with completely resected NSCLC stand out. Two of them use antibodies anti PD-1 (ANVIL and PEARLS) and two more with anti PD-L1 (IMpower-010 and NCT02273375) (Table 1). These trials enroll early stage (IB >4 cm/II/IIIA), complete resected NSCLC patients regardless of tumor PD-L1 level. The adjuvant ICI therapy is administered up to one year and the common primary end point is disease-free survival (DFS).

ANVIL trial (NCT02595944) (39), is a phase III, randomized trial comparing adjuvant nivolumab with observation after surgical resection and standard of care adjuvant chemotherapy and/or radiotherapy for patients with resected stage IB–IIIA NSCLC. The primary endpoints DFS and OS are currently being evaluated.

Keynote-091 (NCT02504372) (40), is a phase III, randomized trial comparing pembrolizumab versus placebo, after standard of care adjuvant chemotherapy in patients with resectable, early-stage NSCLC. The primary endpoint is DFS.

IMpower010 (NCT02486718) (41), is a phase III, randomized, open-label trial recruiting stage IB-IIIA NSCLC resected patients. The trial will evaluate the safety and efficacy of atezolizumab versus best supportive care following adjuvant cisplatin-based chemotherapy. The primary endpoint is DFS, and secondary endpoints include OS and safety.

BR.31. LINC (NCT02273375) is a phase III, randomized trial comparing adjuvant durvalumab administration versus placebo after completely resected NSCLC. The clinical trial is evaluating DFS as primary endpoint.

The possible limitations of these studies include: difficult recruitment (especially the placebo-controlled studies when patients realize they may be coming to the hospital for one-year placebo administration); difficult treatment compliance; unknown duration of treatment; lack of predictive biomarkers; DFS as primary endpoint instead of OS and furthermore, as in other adjuvant studies, inability to define short term surrogate outcomes such as pathologic responses, which implies years to reach conclusions.

### Potentially resectable stage IIIA

In the chemotherapy era, the neoadjuvant treatment has theoretical advantages like: assess of response to

<table>
<thead>
<tr>
<th>NCT</th>
<th>Stage</th>
<th>Phase</th>
<th>Adjuvant duration</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Number of patients</th>
<th>Biomarkers</th>
<th>Status</th>
<th>Primary completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANVIL</td>
<td>NCT02595944</td>
<td>IB, II, IIIA</td>
<td>Nivolumab 240 mg Q4W for up to 1 year</td>
<td>Observation</td>
<td>OS, DFS</td>
<td>903</td>
<td>PD-L1</td>
<td>Active, not recruiting</td>
<td>2024</td>
</tr>
<tr>
<td>KEYNOTE-091</td>
<td>NCT02504372</td>
<td>IB, II, IIIA</td>
<td>Pembrolizumab 200 mg Q3W for up to 1 year</td>
<td>Placebo</td>
<td>DFS</td>
<td>1,080</td>
<td>PD-L1</td>
<td>Active, not recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>PEARLS</td>
<td>NCT02021835</td>
<td>IB, II, IIIA</td>
<td>Atezolizumab 1,200 mg Q3W for 1 year (max. 18 cycles)</td>
<td>Observation</td>
<td>DFS</td>
<td>1,280</td>
<td>PD-L1</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>IMpower010</td>
<td>NCT02486718</td>
<td>IB, II, IIIA</td>
<td>Durvalumab 20 mg/kg 1 year</td>
<td>Placebo</td>
<td>DFS</td>
<td>1,360</td>
<td>PD-L1</td>
<td>Active, not recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>BR.31 LINC</td>
<td>NCT02273375</td>
<td>IB, II, IIIA</td>
<td>Durvalumab 20 mg/kg 1 year</td>
<td>Placebo</td>
<td>DFS</td>
<td>1,360</td>
<td>PD-L1</td>
<td>Active, not recruiting</td>
<td>2023</td>
</tr>
</tbody>
</table>
chemotherapy *in vivo* and this in turn helps identify patients who will potentially benefit from this therapy; perhaps the better locoregional drug delivery because of intact vessels presurgery; better tolerability; early treatment of micrometastatic disease; downstaging with improved resectability and offers an excellent framework for clinical and molecular surrogate markers discovery. However neoadjuvant therapy has potential disadvantages: delay in local therapy due to toxicity, risk progression in chemoresistant patients and pre-operative complications.

Neoadjuvant chemotherapy has not been evaluated as extensively as postoperative. However, several phase III studies have shown that platinum-based induction chemotherapy increases OS (42-44). In stage IIIA (N2) patients, induction chemotherapy increases OS compared to surgery alone (45,46). These results have been confirmed in a later meta-analysis (47). A meta-analysis with 15 randomized trials showed a significant benefit of preoperative chemotherapy on OS [HR 0.87 (0.78–0.96), P=0.007], demonstrating a 5-year OS rate increase of 5%. Neoadjuvant chemotherapy has comparable influence on OS than adjuvant chemotherapy, however more available results support the use of adjuvant treatment.

**Surrogate markers of efficacy outcome**

The use of OS as primary endpoint in resectable NSCLC clinical trials has occasioned prolonged duration of these trials, with the consequent high cost associated and slow development of new therapies. Regardless of their neoadjuvant or adjuvant approach, time from enrollment to publication was in the range of 9 to 13 years. Thus, for faster development of new therapies in early stages of NSCLC there is a need for surrogate markers that anticipate DFS and OS historical endpoints. The assessment of these surrogate markers of efficacy outcome, whether these are clinical, pathological or based in biological parameters, is best analyzed in the neoadjuvant scenario.

Complete surgical resection (48,49), tumor downstaging (50) and complete and major pathologic responses (CPR and MPR, respectively) (51,52) after neoadjuvant chemotherapy, have been associated with improved survival in resectable NSCLC. MPR was first described in the chemotherapy era by at Junker *et al.* Patients with less than 10% viable tumor cells after neoadjuvant treatment (regression grades ≥IIb) had higher 3-year OS rates than those with more than 10% of viable tumor cells in the resection specimen (52% vs. 9%, P=0.02) (53). The robust survival improvement in patients who had MPR compared to other groups was shown by Pataer *et al.* in a broad analysis of 192 stage I–III NSCLC patients resected after neoadjuvant chemotherapy. This study demonstrated that each additional percentage of remaining tumor cell after treatment was linked to a 1% increase in both, the risk of death (HR =1.01, P=0.005) and the risk of disease progression (HR =1.01, P=0.01) (52). Although MPR after induction chemotherapy is significantly associated with hazard ratio for death, its application has not been validated in NSCLC probably due to the low rates of major or complete pathological response achieved with induction chemotherapy, generally close to 20% for major responses and 4% for complete responses (ranging from 0% to 16%) (31,42,47,51,54). This limitation derived from its low frequency could be solved in the near future due to the observed increase of major and complete pathological responses in patients receiving neoadjuvant immunotherapy (17,23). Additionally, pathologic response criteria adapted to ICI are being evaluated (55,56), as well as clinical responses (57), since strong discrepancies between pathological and clinical responses are often observed (17,58). Future studies will shed light in whether major or complete pathologic responses are correlated to survival also in the immunotherapy context and could be implemented as PFS and OS surrogate. This may allow for a faster readout of long-term benefits than in adjuvant studies.

**Clinical trials**

Multiple ICI have been evaluated as neoadjuvant treatment, but their use in this setting remains investigational (*Table 2*).

Recently, Forde, *et al.* (NCT02259621) assessed the feasibility of neoadjuvant PD-1 blockade in a study with 21 NSCLC patients (stage I to IIIA) (17). Two doses of the anti-PD-1 inhibitor nivolumab (3 mg/kg) were administered intravenously every two weeks. Tumor resection was scheduled 4 weeks after neoadjuvant initiation. The study showed no ICI delivery complications with no surgery delay and no relevant postoperative complications. Treatment-related adverse events (TRAEs) of any grade were described in 23% of patients with only one TRAE of grade ≥3. MPR was determined in 45% of patients who underwent surgery and 13% of patients had CPR. However, only 10% of patients had objective clinical responses on post-treatment computer tomography scans (CT-scans). MPR occurred regardless of PD-L1 positivity and tumor mutational burden (TMB) was predictive of pathologic response. Using multiplex immunofluorescence staining a large inflammatory component was observed composed of CD8+ T-cells, PD-1+ cells. At the same time, the study of
the peripheral blood showed a systemic immune response in these patients, composed of T-cell receptors (TCRs) common to those found in the tissue. At median follow up of 30 months, 5 patients had disease progression and 2 patients have died. The 24 months recurrence-free survival rate is 69% (95% CI, 51 to 93) (59).

LCMC3 trial (NCT02927301) (60,61), is a phase II single-arm study of neoadjuvant anti-PD-L1 (atezolizumab) in resectable (stages IB to selected IIIB, T3N2) NSCLC patients. For the last interim efficacy analysis (5 Sep 2018 data cut) they reported on the first 101 of 180 planned patients (61). By RECIST, 6/82 patients had partial response, 72 had stable disease and 4 had progressive disease. The MPR rate was 18% (95% CI, 11 to 28) 15/82, 4 patients had CPR (5%). There was one unrelated grade 5 adverse events (AEs) and 16 grade 3 or 4 AEs (three treatment related), and surgery was delayed in one patient due to grade 3 immune-mediated pneumonitis. The biological correlative studies are ongoing.

NEOSTAR study (NCT03158129) is a phase II study of ICI induction for untreated stage I–IIIA (single N2) NSCLC patients. Three doses of preoperative nivolumab 3 mg/kg monotherapy or in combination with ipilimumab 1 mg/kg are administered to patients every two weeks (62). Five of the 31 patients did not undergo tumor resection due to different causes (one had hypoxemia grade 3, two had high surgical risk and two were no longer resectable). MPR rate in the remaining patients was 28% and 31% in the nivolumab or nivolumab plus ipilimumab trial arms, respectively. In ASCO 2019 updated data were presented (63) showing 39 of 44 underwent surgery with 89% resectability. The MPR rate was 24% overall, 17% with nivolumab and 33% with the combination therapy. Secondary AEs were 4%, including 2 bronchopleural fistulas and 8 air leaks.

Chemoimmunotherapy has demonstrated superiority compared with chemotherapy alone in patients with metastatic NSCLC. This led to study the role of chemoimmunotherapy with surgery in earlier-stage NSCLC.

NADIM trial (NCT03081689) (23) is a prospective, open-label, single-arm phase II trial, evaluating the safety and efficacy of neoadjuvant chemotherapy (paclitaxel 200 mg/m² + carboplatin AUC 6 IV every 3 weeks) plus nivolumab (360 mg) followed by adjuvant nivolumab (240 mg IV every 2 weeks for 4 months and 480 mg IV every 4 weeks for 8 months) in 46 patients with resectable stage IIIA (N2 or T4) NSCLC. The primary endpoint was PFS at 24 months. Efficacy was evaluated using objective pathological response criteria. The last results were presented in WCLC 2019 (58). Forty-one of 46 patients had undergone surgery and all tumors were resectable with R0 resection. Intention to treat analysis showed that 34 patients (83%, 95% CI, 68 to 93) achieved MPR of which 24 (59%, 95% CI, 42 to 74) were CPR. This CPR rate is the highest ever seen in this context. Downstaging was observed in 38 (93%, 95% CI, 80 to 98) of cases. The median follow-up was 13.8 and 12 months PFS was 95.7% (95% CI, 84 to 99). This is the first multi-center study to explore chemotherapy and immunotherapy in the neoadjuvant setting in stage IIIA. A new randomized phase II clinical trial comparing the same neoadjuvant chemotherapy plus nivolumab schema followed by a shorter adjuvant nivolumab monotherapy for 6 months, versus standard chemotherapy alone, is currently ongoing (NADIM II, ClinicalTrials.gov number, NCT03838159).

The study of Shu and collaborators, NCT02716038, is another study with combined chemotherapy and ICI therapy. In this trial, four cycles of atezolizumab plus carboplatin-nabpaclitaxel reported an MPR in 17 (57%) of 30 patients included. The most common grade 3–4 AEs were neutropenia, thrombopenia and transaminases elevation (64).

This led to several ongoing phases III trials with this approach (Table 2). They all differ in certain aspects of their design.

The KEYNOTE-671 trial (NCT03425643) (65), double-blind, randomized 1:1 placebo-controlled, phase III trial testing four cycles of concomitant neoadjuvant platinum doublet plus pembrolizumab followed by surgery and 13 cycles of adjuvant pembrolizumab for resectable stage IIB or IIIA NSCLC patients. Although its solid design, using event-free survival and OS as primary endpoints, the adjuvant placebo administration can be a drawback for patient recruitment.

The open-label Checkmate-816 trial (NCT02998528) (66), evaluates the safety and effectiveness of neoadjuvant nivolumab plus platinum-doublet followed by surgery and postoperative standard of care versus chemotherapy alone. Initially, the study planned an additional arm testing nivolumab plus ipilimumab combination, however it was closed on December 2018. This study will compare EFS and CPR rate among participants treated with neoadjuvant nivolumab plus platinum doublet chemotherapy vs. participants treated with platinum doublet chemotherapy in stage IB-IIIA NSCLC.

The IMpower-030 (NCT03456063) (67) is a double-
<table>
<thead>
<tr>
<th>Trial/sponsor</th>
<th>NTC</th>
<th>Stage</th>
<th>Phase</th>
<th>Experimental arm</th>
<th>Neoadjuvant duration</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Number of patients</th>
<th>Resected patients</th>
<th>CPR</th>
<th>MPR</th>
<th>Biomarkers</th>
<th>Status</th>
<th>Primary completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKCCC-JHU</td>
<td>NCT02259621</td>
<td>IB, II, IIIA</td>
<td>II</td>
<td>Nivolumab</td>
<td>3 cycles Q2W</td>
<td>none</td>
<td>Safety</td>
<td>22</td>
<td>21</td>
<td>2 (10%)</td>
<td>9 (45%)</td>
<td>PD-L1, TMB, Recruiting</td>
<td>Recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>LCMC3</td>
<td>NCT02927301</td>
<td>IB–IIIB</td>
<td>II</td>
<td>Atezolizumab</td>
<td>2 cycles Q3W</td>
<td>none</td>
<td>MPR</td>
<td>180</td>
<td>82</td>
<td>4 (5%)</td>
<td>15 (18%)</td>
<td>PD-L1, TMB</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>NEOSTAR</td>
<td>NCT03158129</td>
<td>I–IIIA</td>
<td>II</td>
<td>Nivolumab or Nivolumab + Ipi</td>
<td>3 cycles Q2W</td>
<td>ICI + cCT</td>
<td>Nivolumab + 1 dose Ipi</td>
<td>88: Nivolumab</td>
<td>39</td>
<td>8: Nivolumab</td>
<td>11: Nivolumab</td>
<td>PD-L1, TCR</td>
<td>Recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>NADIM</td>
<td>NCT03081689</td>
<td>IIIA</td>
<td>II</td>
<td>Nivolumab + cCT – Nivolumab (adjuvant)</td>
<td>3 cycles Q3W</td>
<td>none</td>
<td>24 months PFS</td>
<td>46</td>
<td>41</td>
<td>24 (59%)</td>
<td>34 (83%)</td>
<td>PD-L1, TMB, Recruiting</td>
<td>Recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>Columbia University</td>
<td>NCT02716038</td>
<td>IB–IIIB</td>
<td>II</td>
<td>Atezolizumab + cCT – SoC (adjuvant)</td>
<td>4 cycles Q2W</td>
<td>none</td>
<td>MPR</td>
<td>30</td>
<td>11</td>
<td>3/14 (21%)</td>
<td>7/14 (50%)</td>
<td>PD-L1, multiplex IHC, TCR, ctDNA</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>SAKK</td>
<td>NCT02572843</td>
<td>IIIA</td>
<td>II</td>
<td>Durvalumab + cCT – Durvalumab (adjuvant)</td>
<td>3 cycles Q3W cCT + 2 cycles Q2W</td>
<td>Durvalumab – Durvalumab for up to 1 year</td>
<td>none</td>
<td>EFS</td>
<td>68</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>PD-L1, Active, not recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>NADIM 2</td>
<td>NCT03838159</td>
<td>IIIA–IIIB</td>
<td>II</td>
<td>Nivolumab + cCT</td>
<td>3 cycles Q2W – Nivolumab for up 6 months</td>
<td>CT</td>
<td>CPR</td>
<td>90</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>PD-L1, TMB, Recruiting</td>
<td>Recruiting</td>
<td>2022</td>
</tr>
<tr>
<td>KEYNOTE-671</td>
<td>NCT03425643</td>
<td>II–IIIA–IIIB</td>
<td>III</td>
<td>Pembrolizumab 4 cycles Q3W + Placebo</td>
<td>EFS, OS</td>
<td>786</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>PD-L1, Recruiting</td>
<td>2024</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 (continued)
<table>
<thead>
<tr>
<th>Trial/sponsor</th>
<th>NTC</th>
<th>Stage</th>
<th>Phase</th>
<th>Neoadjacent arm duration</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary Endpoint</th>
<th>Number of patients</th>
<th>Resected patients</th>
<th>CPR</th>
<th>MPR</th>
<th>Biomarkers Status</th>
<th>Primary completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Checkmate 816</td>
<td>NCT02939828</td>
<td>IB–IIIA</td>
<td>III</td>
<td>3 cycles Q3W CT</td>
<td>Nivolumab + cCT or Nivolumab (closed)</td>
<td>3 cycles Q3W Placebo</td>
<td>MPR, EFS</td>
<td>CPR</td>
<td>350</td>
<td>NA</td>
<td>NA</td>
<td>Exploratory biomarkers</td>
<td>2020</td>
</tr>
<tr>
<td>IMPower030</td>
<td>NCT03456063</td>
<td>II–IIIA–IIIB</td>
<td>III</td>
<td>Specified dose on specified days</td>
<td>Atezolizumab + cCT – 16 cycles Q3W</td>
<td>Placebo</td>
<td>SoC</td>
<td>EFS</td>
<td>374</td>
<td>NA</td>
<td>NA</td>
<td>Exploratory biomarkers</td>
<td>2023</td>
</tr>
<tr>
<td>Checkmate 77T</td>
<td>NCT04428579</td>
<td>II–IIB</td>
<td>III</td>
<td>4 cycles Q3W Placebo</td>
<td>Nivolumab (adjuvant)</td>
<td>Placebo</td>
<td>MPR, EFS</td>
<td>CPR</td>
<td>452</td>
<td>NA</td>
<td>NA</td>
<td>Exploratory biomarkers</td>
<td>2024</td>
</tr>
<tr>
<td>AEGEAN</td>
<td>NCT03880134</td>
<td>IIA–IIIA–IIIB</td>
<td>III</td>
<td>4 cycles Q3W Placebo</td>
<td>Durvalumab (adjuvant)</td>
<td>Placebo</td>
<td>MPR, EFS</td>
<td>CPR</td>
<td>830</td>
<td>NA</td>
<td>NA</td>
<td>PD-L1 Recruiting</td>
<td>2024</td>
</tr>
</tbody>
</table>

NTC, national clinical trial; MPR, major pathological response; CPR, complete pathological response; AEs, adverse events; TCR, T cell receptor; ctDNA, circulating tumor DNA; TMB, tumor mutational burden; cCT, concurrent chemotherapy; PFS, progression-free survival; IHC, immunohistochemistry; CT, chemotherapy; SoC, standard of care; EFS, event-free survival; OS, overall survival; NA, not applicable.
blind, randomized study of resectable stage II, IIA and IIB (T3N2) NSCLC patients. The study will determine the efficacy of 4 cycles of neoadjuvant atezolizumab (1,200 mg Q3W), in combination with a platinum-based doublet followed by surgery and postoperative atezolizumab versus neoadjuvant platinum-based doublet followed by surgery and supportive care. Trial has MPR as primary endpoint.

Unresectable tumors

Most patients diagnosed with stage III NSCLC are considered inoperable by a multidisciplinary team for both medical and anatomical reasons. Local-regionally unresectable NSCLC tumors have been traditionally treated with concurrent chemoradiation, obtaining more clinical benefit than sequential therapy or radiation alone (68-70). Consequently, weekly low-dose platinum-taxane or platinum doublet used as concurrent chemoradiation has been the standard of care until very recently, but only 15–20% of patients are alive 5 years after treatment (71,72).

However, the actual standard treatment for local-regionally advanced NSCLC which is not resectable was set up based on the results of the PACIFIC trial (NCT02125461) (73,74). In this study, 713 patients with unresectable stage III NSCLC were randomly assigned at 1:2 to standard chemoradiation or chemoradiation followed by an anti-PD-L1 antibody, durvalumab (administered intravenously 10 mg per kilogram, every 2 weeks for up 12 months). Primary endpoints were overall survival (OS) at 24 months and progression free survival (PFS), both of which resulted in a significant improvement in the durvalumab arm (66.3% OS and 17.2% PFS) versus the placebo arm (55.6% and 5.6%, respectively). Key secondary endpoints shown improved results in the durvalumab groups vs. placebo; considering overall response rate (30% vs. 17.8%), median duration of response (not reached at 27.4 vs. 18.4%), time to death or distant metastasis (28.3 vs. 16.2), and time to second progression (28.3 vs. 17.1). Incidence of metastasis was lower in the durvalumab arm (22.5% vs. 33.8%), and also patients receiving durvalumab had a lower incidence of brain metastasis (6.3% vs. 11.8%). No any-grade all-causality adverse events (AEs) showed a significant difference between groups, and even though any-grade pneumonitis trended to be higher in the durvalumab group (33.9% vs. 24.8%), grade 3/4 pneumonitis rates were similar (3.6% in the durvalumab arm vs. 3% in the placebo). The clinical benefit in the PACIFIC trial did not correlated with PD-L1 status, but it should be noted that PD-L1 testing was not mandatory, as no threshold was defined in inclusion criteria. PD-L1 status of 37% of patients was unknown, and safety outcomes were independent of PD-L1 too. Despite the U.S. Food and Drug Administration approved the use of durvalumab in local-regionally advanced NSCLC in February 2018, the European Medicines Agency limited the use of the ICI only to patients who were immunohistochemistry (IHC) positive.

Results from PACIFIC trial have focused new interest in therapies combining immunotherapy with other modalities of treatment. Several trials are actually recruiting patients when they have finished concurrent chemoradiation, and treating them with ICI. One to mention is the PACIFIC 6 (NCT03693300), which have changed the dose from 10 mg/kg of durvalumab every 2 weeks administered in the original PACIFIC trial to 1,500 mg every 4 weeks.

Other clinical trials are evaluating the effect of immunotherapy with concurrent chemoradiation followed by maintenance immunotherapy. The DETERRED trial (75) is currently ongoing, and it is divided in two parts, both of them consist of concurrent chemoradiation followed by 1 year of atezolizumab consolidation therapy, but differentiated in the administration of additional atezolizumab to concurrent chemoradiation in part 2. Its primary endpoints evaluate safety and feasibility, and results shown even higher grade 3 AEs in first group (40% vs. 23%). There was no difference in OS between both groups (79%), however PFS was relatively higher in part 2 (50% in part 1 vs. 57% in part 2). However, evaluation of PD-L1 level showed no significant differences in cancer recurrence. In summary, the DETERRED trial demonstrated the safety of adding immunotherapy to concurrent chemoradiation.

Nowadays the real benefit of chemotherapy is being discussed, and it is theorized that the true benefit of chemoradiation belongs to radiosensitization, and that immunotherapy could reach the same clinical benefit more safely. Ongoing studies (NCT02221739 and NCT03391869) shows that radiotherapy combined with checkpoint inhibitors treatment is safe and tolerable. There is no strong evidence of an abscopal effect in immunotherapy, but the PACIFIC study improvements in local-regional control and reduction in distant metastasis give clinical evidence that support this hypothesis.

The LUN 14-179 (NCT02343952) study is a phase II, single arm trial consisting of concurrent chemoradiation treatment followed by pembrolizumab in patients with unresectable stage III NSCLC. It showed efficacy and
safety, and it achieved an OS 80.5% at 1 year and 68.7% at 2 years. Median PFS was 15.4 months; and 12, 18, and 24-month PFS were 59.9%, 49.5% and 45.4% respectively (76).

In the phase II NICOLAS trial (NCT02434081), nivolumab is administered concurrently with radiotherapy followed by nivolumab consolidation therapy for up to 1 year. Eighty-two patients were recruited with median follow-up of 13.4 months. Safety analysis showed no unexpected AEs or increased toxicities, and most frequent were anemia, fatigue and pneumonitis. These results provide evidence that the addition of nivolumab to concurrent chemoradiotherapy is safe and tolerable. Following that, the 1-year PFS is still under evaluation and will be assessed in an expanded patient cohort (77).

The SPRINT trial (NCT03523702) is replacing concurrent chemotheraphy with pembrolizumab in patients with high status of PD-L1 (>50%), while patients under 50% are treated with concurrent chemoranadation. An additional trial (NCT03818776) is evaluating concurrent durvalumab with radiotherapy in patients with stage III NSCLC not eligible for concurrent chemoradiation therapy.

Even though the PACIFIC study represents a significant advance in the treatment of unresectable stage III NSCLC, there are multiple unknown factors such as the optimal timing of delivering of the immunotherapy, duration of immunotherapy administration, the most appropriate immunotherapeutic agent, the use of concomitant medications and possible autoimmune side effects that should be addressed with ongoing and future clinical trials, indexed in Table 3.

**Predictive biomarkers: PD-L1, TMB and emerging biomarkers**

The strikingly different behavior between the current standard of care and this new immunotherapy scheme, especially with chemoimmunotherapy, make the study of their molecular differences a key area for treatment improvement. However, due to the novelty of these therapies, the mechanism responsible for the differential response among patients to these therapies remains unknown.

TMB has recently emerged as a possible biomarker to predict NSCLC response. Primary targets of many tumor immune responses are neoantigen peptides derived from mutations, and high TMB usually correlates with higher response rates in carcinogen-driven cancers such as NSCLC. In two independent cohorts of NSCLC patients treated with pembrolizumab, results shown an association between higher TMB and enhanced therapeutic efficacy, PFS and objective response (78), followed by significant associations between high TMB and ICI response in later NSCLC studies (17,79-81). Furthermore, in the mentioned study a correlation between TMB and smoking status have been associated with better clinical benefit, as long as tumors from smokers have relatively high TMB (78). However, while the link between TMB and immunotherapy response is mostly solid, in some cases there are some patients with high TMB who are non-responders and vice versa.

On the other hand, it is supposed to be necessary certain expression of PD-L1 for anti-PD-1 therapy to have a real effect. Consequently, immunohistochemistry assays have been developed to define PD-L1 protein expression for clinical use. There are several clinical trials whose PD-L1 status correlates with response, such as KEYNOTE-001. In this study, the objective response rate among patients with PD-L1 ≥50% had a significant increase compared to all the patients (45% vs. 19.4%) (82). In NEOSTAR clinical trial, pre-treatment tumor PD-L1 levels was noteworthy higher in responders vs. non-responders (80% vs. 1%), and the median percentage of viable tumor was remarkable lower in tumors with PD-L1 > 1% vs. PD-L1 ≤1% (20% vs. 80%). Also in LCMC3 trial the percentage of patients with MPR was higher in PD-L1+ (29% PD-L1+ vs. 8% PD-L1−). Additionally, 5 of 44 (11%) with PD-L1 TPS <50% and 7 of 20 (35%) with PD-L1 TPS >50% had MPR.

Despite this, determination of PD-L1 status remains an imperfect biomarker and not always is capable of predict an accurate immune response. Multiple studies in NSCLC tumors have detected no association between PD-L1 status and response (83,84). Potential reason for these contradictory results could be the temporal and spatial heterogeneous PD-L1 expression, the use of different detection assays, and non-standardized criteria and cut-offs for evaluating positivity. Recently, in the Keynote 189 phase III trial (85), PD-L1 status was predictive of response to pembrolizumab plus chemotherapy treatment at all levels of PD-L1. However, as the PD-L1 threshold was relaxed, the predictive effect of PD-L1 positivity notably decreased.

Regardless of the type of treatment, the neoadjuvant scenario is ideal as it allows us to study the pre-treatment immune status of a tumor (which would correspond to a tumor in the immune evasion phase) and, on the same
<table>
<thead>
<tr>
<th>Trial/sponsor</th>
<th>NTC</th>
<th>Stage</th>
<th>Phase</th>
<th>Experimental arm</th>
<th>Duration</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Number of patients</th>
<th>Status</th>
<th>Primary completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACIFIC 6</td>
<td>NCT03693300</td>
<td>III</td>
<td>II</td>
<td>Durvalumab</td>
<td>26 cycles Q4W</td>
<td>None</td>
<td>Safety</td>
<td>150</td>
<td>Recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>MP-LALC</td>
<td>NCT03379441</td>
<td>III</td>
<td>II</td>
<td>Pembrolizumab</td>
<td>35 cycles Q3W</td>
<td>None</td>
<td>OS</td>
<td>126</td>
<td>Not yet recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>LUN14-170</td>
<td>NCT02343952</td>
<td>III</td>
<td>II</td>
<td>Pembrolizumab</td>
<td>Q3W for up to 1 year</td>
<td>None</td>
<td>Time to death or distant metastasis</td>
<td>93</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>CONSIST</td>
<td>NCT03884192</td>
<td>III</td>
<td>III</td>
<td>Sintilimab</td>
<td>Q3W for up to 1 year</td>
<td>Observation</td>
<td>PFS</td>
<td>162</td>
<td>Recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>LUN16-081</td>
<td>NCT03285321</td>
<td>IIIA/IIIB</td>
<td></td>
<td>Pembrolizumab + Ipilimumab</td>
<td>6 cycles (Nivolumab Q2W + Ipil Q6W)</td>
<td>None</td>
<td>PFS</td>
<td>108</td>
<td>Recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>COAST</td>
<td>NCT03822351</td>
<td>III</td>
<td>II</td>
<td>2 arms: Durvalumab + Oleoclumab and Durvalumab + Monalizumab</td>
<td>12 months</td>
<td>Durvalumab</td>
<td>ORR</td>
<td>300</td>
<td>Recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>CLOVER NSCLC arms 1-3</td>
<td>NCT03509012</td>
<td>III</td>
<td>I</td>
<td>Durvalumab + cCRT</td>
<td>Not specified</td>
<td>CRT</td>
<td>DLT/AES</td>
<td>360</td>
<td>Active, not recruiting</td>
<td>2022</td>
</tr>
<tr>
<td>PACIFIC 2</td>
<td>NCT03519971</td>
<td>III</td>
<td>III</td>
<td>Durvalumab + cCRT (consolidation)</td>
<td>Q4W</td>
<td>Placebo + CRT (consolidation)</td>
<td>PFS/ORR</td>
<td>328</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>KEYNOTE-799</td>
<td>NCT03631784</td>
<td>III</td>
<td>II</td>
<td>Pembrolizumab + cCRT − Pembrolizumab (consolidation)</td>
<td>Pembrolizumab 3 cycles Q3W + cCRT (1 dose at day 1 + 6 doses weekly from day 21); Pembrolizumab 14 cycles Q3W</td>
<td>None</td>
<td>Grade ≥3 pneumonitis/% of patients with CR or PR</td>
<td>216</td>
<td>Recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>NICOLAS</td>
<td>NCT02434081</td>
<td>IIIA/B</td>
<td>II</td>
<td>Nivolumab + cCRT − Nivolumab (consolidation)</td>
<td>3 cycles Q4W, Up to 1 year</td>
<td>None</td>
<td>Grade ≥3 pneumonitis</td>
<td>94</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>AFT-16</td>
<td>NCT03102242</td>
<td>IIIA/B</td>
<td>II</td>
<td>Atezolizumab − CT− Atezolizumab</td>
<td>4 cycles Q3W, 6 cycles Q1W, 2 cycles Q3W, Q3W up to 1 year</td>
<td>None</td>
<td>DCR</td>
<td>64</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>DETERRED</td>
<td>NCT02525757</td>
<td>II–III</td>
<td>II</td>
<td>Atezolizumab + cCRT − Atezolizumab</td>
<td>10 cycles, 2 cycles Q3W, − Atezolizumab + cCT Up to 1 year; CT and CRT was administered Q1W and Atezolizumab Q3W</td>
<td>CRT − Atezolizumab</td>
<td>Time to toxicity</td>
<td>52</td>
<td>Active, not recruiting</td>
<td>2020</td>
</tr>
</tbody>
</table>

Table 3 (continued)
<table>
<thead>
<tr>
<th>Trial/sponsor</th>
<th>NTC</th>
<th>Stage</th>
<th>Phase</th>
<th>Experimental arm</th>
<th>Duration</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Number of patients</th>
<th>Status</th>
<th>Primary completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMD Serono</td>
<td>NCT03840902</td>
<td>III</td>
<td>II</td>
<td>M7824 + cCRT − M7824</td>
<td>6 weeks to 1 year; M7824 was administered Q2W</td>
<td>Placebo + cCRT − Durvalumab</td>
<td>PFS</td>
<td>350</td>
<td>Recruiting</td>
<td>2024</td>
</tr>
<tr>
<td>PASTURE</td>
<td>NCT03945227</td>
<td>III</td>
<td>II</td>
<td>cCRT + PDR001 − PDR001</td>
<td>8 weeks (cCRT: Q1W, PDR001: 2 cycles Q4W); Q4W for up to 1 year</td>
<td>CRT − PDR001</td>
<td>PFS</td>
<td>200</td>
<td>Not yet recruiting</td>
<td>2022</td>
</tr>
<tr>
<td>POD1UM-301</td>
<td>NCT04203511</td>
<td>III</td>
<td>II</td>
<td>INCMGA00012 + cCRT INCMGA00012: 4 cycles − INCMGA00012</td>
<td>Placebo + cCRT − Placebo</td>
<td>Placebo</td>
<td>PFS</td>
<td>360</td>
<td>Not yet recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>SPRINT</td>
<td>NCT03523702</td>
<td>II/III</td>
<td>II</td>
<td>Pembrolizumab − RT − Pembrolizumab (&lt;50% PD-L1)</td>
<td>3 cycles Q3W, daily for 4 weeks, 12 cycles Q3W</td>
<td>CRT (&lt;50% PD-L1)</td>
<td>PFS</td>
<td>63</td>
<td>Recruiting</td>
<td>2020</td>
</tr>
<tr>
<td>PARTICLE-D</td>
<td>NCT03818776</td>
<td>IIA–IIIC</td>
<td>I</td>
<td>Durvalumab + cRT (2 arms with different doses of cRT)</td>
<td>Durvalumab: 13 cycles Q4W, RT: 60 CGyE in 20 fractions or 69 CGyE in 23 fractions</td>
<td>None</td>
<td>DLT</td>
<td>27</td>
<td>Recruiting</td>
<td>2021</td>
</tr>
<tr>
<td>DUART</td>
<td>NCT04249362</td>
<td>III</td>
<td>II</td>
<td>RT − Durvalumab (2 arms with different doses of RT)</td>
<td>Standard vs. palliative RT, Durvalumab Q4W for up to 12 months</td>
<td>None</td>
<td>Grade ≥3 AEs</td>
<td>150</td>
<td>Not yet recruiting</td>
<td>2022</td>
</tr>
<tr>
<td>TRADE-hypo</td>
<td>NCT04351256</td>
<td>III</td>
<td>II</td>
<td>Durvalumab + cRT (2 arms with different doses of cRT)</td>
<td>Durvalumab: 12 cycles Q4W, RT: hypofractioned for 4 weeks vs. conventionally fractioned for 6 weeks</td>
<td>None</td>
<td>Toxicity, ORR</td>
<td>88</td>
<td>Not yet recruiting</td>
<td>2023</td>
</tr>
<tr>
<td>NCI</td>
<td>NCT04310020</td>
<td>II/III</td>
<td>II</td>
<td>RT − Atezolizumab</td>
<td>RT: 5 days/week for 3 weeks, Atezolizumab: 17 cycles Q3W</td>
<td>None</td>
<td>Grade ≥3 AEs</td>
<td>47</td>
<td>Not yet recruiting</td>
<td>2022</td>
</tr>
</tbody>
</table>

NTC, national clinical trial; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; CRT, chemoradiation; cCRT concurrent chemoradiation; DLT, dose limiting toxicities; AES, adverse events; CR, complete response; PR, partial response; CT, chemotherapy; DCR, disease control rate; cCT, concurrent chemotherapy; RT, radiotherapy; cRT, concurrent radiotherapy.
individual, to study his post-treatment tumor, evaluating the changes in the tumor immune microenvironment and their relationship with the degree of treatment response and prognosis of the patient.

An interesting way to assess the status of the antitumor immune response is the deep sequencing of the TCR locus. During T cell maturation, their TCR locus suffer somatic rearrangements allowing T cells to recognize different antigens including tumor antigens. Cha et al., showed on melanoma and prostate patients treated with ipilimumab that massive sequencing on TCR locus from PBMCs allow them to correlate T cell repertoire with response to immunotherapy treatment (86). Later on, Akyüz et al., on another study with 18 patients treated with anti-PD-1 found a clear pattern of diversification of T cell clones correlated with the control of the disease (87). Recently, Forde et al. have described that the number of T cells clones shared in tumor and in peripheral blood increased after anti PD-1 treatment, in 8 of 9 patients with NSCLC (17). Therefore, the massive sequencing of the TCR locus is positioned as an interesting technique for the evaluation of the antitumor immune response.

**Study limitations**

Limitations of this overview include, but are not limited to, the intrinsic stage IIIA heterogeneous population, in which the definition of resectable versus unresectable is variable depending always on the decision of a multidisciplinary committee, hindering trials comparisons; addressing a topic with a large number of trials and fast development; discussing interim analysis results, that could change with final study conclusions; and focusing on immunotherapies based primarily on blocking PD-(L)1 or CTLA4, because of space constraints and current relevance.

**Conclusions**

Immunotherapy has revolutionized the treatment of advanced stages of lung cancer; becoming locally advanced stages its next challenge. As bring up in this review, numerous trials are currently evaluating the role of immunotherapy alone or in combination with other therapies, in both adjuvant and neoadjuvant setting.

Given the management complexity and intermediate prognosis of stage IIIA disease, circumstances such as the combination with other therapies, the treatment timing, and the patient selection through predictive markers, will be key to immunotherapy success in this scenario. Likewise, the increase in pathological response rates anticipated with immunotherapy opens the possibility to establish the MPR rate as a surrogate to neoadjuvant treatment. Preliminary results seem to favor neoadjuvant to adjuvant treatment, and through the NADIM trial, the chemoimmunotherapy combination seems to stand out.

In the next few years, the results of ongoing trials will answer whether immunotherapy can be implemented and to what extent is capable of transforming stage IIIA from a lethal condition to a curable disease.

**Acknowledgments**

Funding: Work in the authors’ laboratories was supported by “Instituto de Salud Carlos III” (ISCIII) PI19/01652 grant, and European Union’s Horizon 2020 research and innovation programme, CLARIFY 875160 grant, to M.P. A.C-B, received a Spanish Lung Cancer Group (SLCG) grant and is supported by a ISCIII “Sara Borrell” contract CD19/00170.

**Footnote**

Provenance and Peer Review: This article was commissioned by the Guest Editors (Fabrizio Minervini and Marco Scarci) for the series “Controversies in the Management of Stage IIIA Non-Small-Cell Lung Cancer” published in Current Challenges in Thoracic Surgery. The article was sent for external peer review organized by the Guest Editors and the editorial office.

**Funding**

Work in the authors’ laboratories was supported by “Instituto de Salud Carlos III” (ISCIII) PI19/01652 grant, and European Union’s Horizon 2020 research and innovation programme, CLARIFY 875160 grant, to M.P. A.C-B, received a Spanish Lung Cancer Group (SLCG) grant and is supported by a ISCIII “Sara Borrell” contract CD19/00170.

**Conflicts of Interest**

All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/ccts-20-82). The series “Controversies in the Management of Stage IIIA Non-Small-Cell Lung Cancer” was commissioned by the editorial office without any funding or sponsorship. VC reports personal fees from Roche, BMS, MSD, AstraZeneca, Boehringer, Novartis and Takeda., outside the submitted work. MP reports grants and personal fees from BMS, personal fees from Astra Zeneca, Roche, MSD and Takeda, outside the submitted work. The authors have no other conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


Cancer Inst 2011;103:1452-60.